Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 23, 2017
Pharmacy Choice - Pharmaceutical News - Analyst Activity Raymond James Financial, Inc. Initiates Coverage On Antares Pharma (NASDAQ:ATRS) With a Strong-Buy - April 23, 2017

Pharmacy News Article

 4/21/17 - Analyst Activity Raymond James Financial, Inc. Initiates Coverage On Antares Pharma (NASDAQ:ATRS) With a Strong-Buy

Analyst Ratings For Antares Pharma (NASDAQ:ATRS)

Today, Raymond James Financial, Inc. initiated coverage on Antares Pharma (NASDAQ:ATRS) with a Strong-Buy with a price target of $4.30.

There are 2 buy ratings, 1 strong buy rating on the stock.

The current consensus rating on Antares Pharma (NASDAQ:ATRS) is Buy (Score: 3.33) with a consensus target price of $3.10 per share, a potential 12.32% upside.

Some recent analyst ratings include

  • 4/20/2017-Raymond James Financial, Inc. initiated coverage with a Strong-Buy rating.
  • 8/13/2016-Piper Jaffray Companies Reiterated Rating of Overweight.
  • 5/10/2016-Jefferies Group LLC Reiterated Rating of Buy.
  • 9/25/2015-Oppenheimer Holdings Inc. Reiterated Rating of Buy.

Dividend information for Antares Pharma (NASDAQ:ATRS)

.
Recent Insider Trading Activity For Antares Pharma (NASDAQ:ATRS)
Antares Pharma (NASDAQ:ATRS) has insider ownership of 10.77% and institutional ownership of 33.60%.

  • On 4/5/2017 Robert F Apple, CEO, sold 40,000 with an average share price of $3.00 per share and the total transaction amounting to $120,000.00. View SEC Filing
  • On 4/4/2017 Leonard S Jacob, Director, sold 41,762 with an average share price of $2.89 per share and the total transaction amounting to $120,692.18. View SEC Filing
  • On 4/4/2017 Robert F Apple, CEO, sold 37,000 with an average share price of $3.00 per share and the total transaction amounting to $111,000.00. View SEC Filing
  • On 4/3/2017 Leonard S Jacob, Director, sold 20,000 with an average share price of $2.88 per share and the total transaction amounting to $57,600.00. View SEC Filing
  • On 3/31/2017 Thomas J Garrity, Director, sold 30,000 with an average share price of $2.91 per share and the total transaction amounting to $87,300.00. View SEC Filing
  • On 12/9/2016 Fred M Powell, Insider, bought 100,000 with an average share price of $2.03 per share and the total transaction amounting to $203,000.00. View SEC Filing
  • On 3/21/2016 Peter J Graham, SVP, bought 20,000 with an average share price of $0.77 per share and the total transaction amounting to $15,400.00. View SEC Filing

About Antares Pharma (NASDAQ:ATRS)
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.

Recent Trading Activity for Antares Pharma (NASDAQ:ATRS)
Shares of Antares Pharma closed the previous trading session at 2.76 up +0.04 1.47% with 1,153,406 shares trading hands.

The post Analyst Activity Raymond James Financial, Inc. Initiates Coverage On Antares Pharma (NASDAQ:ATRS) With a Strong-Buy appeared first on Market Exclusive.



© Market Exclusive 2017

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Apr 24: A Look Inside the Top 200 Drugs
Apr 25: Skin Infections: Focus on Cellulitis & MRSA
Apr 26: Medical Marijuana: Examining the Science, Not the Politics
Apr 27: What's New? New Treatments for Type 2 Diabetes
Apr 30: Using Effective Communication to Reduce Medication Errors
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415